Cancer Therapy Market Research by 2020 Top Countries Data, Key Players, Industry Revenue, Demand Status and Investments Plans Forecast to 2024 – The…

Several big pharmaceutical companies, such as Pfizer and Eli lily, have also started these programs to help uninsured patients who are suffering from chronic diseases. Thus, a large number of uninsured patients, suffering from cancer, can also undergo cancer therapies, which is likely to augment the growth of the market.

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999546

Key Market Trends:

The Target Therapy Segment is Expected to show the Fastest Growth in the Forecast Period

The target therapy segment is expected to show the highest CAGR of 9.68% during the forecast period. The target therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells, while sparing the toxicity to off-target cells.

The breast cancer segment is belived to account for the largest market size over the forecast period. This is majorly attrobuted to the higher and continuously increaisng prevalence of breast cancer acoss the world. As per estimates provided by the Breast Cancer Organization in 2018, it is estimated that over 2,66,120 new cases of invasive breast cancer are expected to be diagnosed in women in the United States, along with 63,960 new cases of non-invasive (in situ) breast cancer.

North America Currently Dominates the Cancer Therapy Market and is Expected to Continue in the Forecast Period

North America currently dominates the market for cancer therapy and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increased adoption of cancer therapy. The United States holds majority of the market in the North American region, due to the rising prevalence of cancer in the country. According to the National Cancer Institute (NCI), in 2016, 1.6 million people suffered from cancer, and around 0.5 million people died from cancer. This figure indicates that the prevalence of cancer is rapidly increasing in the United States.

Competitive Landscape:

Most of the companies present in the market are efficient at the technological front but require significant support for enhancing their services and expanding their businesses. Thus, mergers and acquisitions offer significant opportunities to gain the attention of a large number of providers across developed regions.

Purchase this Report (Price 4500 USD for a single-user license) https://www.industryresearch.co/purchase/13999546

Detailed TOC of Cancer Therapy Market Report 2020-2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Increasing Patient Assistance Programs (PAPs) 4.2.2 Growing Government Initiatives for Cancer Awareness 4.2.3 Rising Prevalence of Cancer Worldwide 4.2.4 Strong R&D Initiatives from Key Players 4.3 Market Restraints 4.3.1 Fluctuation in Reimbursement Policies 4.3.2 High Cost of Cancer Therapies 4.4 Porters Five Force Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Treatment Type 5.1.1 Chemotherapy 5.1.2 Targeted Therapy 5.1.3 Immunotherapy 5.1.4 Hormonal Therapy 5.1.5 Other Treatment Types 5.2 By Cancer Type 5.2.1 Blood Cancer 5.2.2 Breast Cancer 5.2.3 Prostate Cancer 5.2.4 Gastrointestinal Cancer 5.2.5 Gynecologic Cancer 5.2.6 Respiratory/Lung Cancer 5.2.7 Other Cancer Types 5.3 By End User 5.3.1 Hospitals 5.3.2 Spcialty Clinics 5.3.3 Cancer and Radiation Therapy Centers 5.4 Geography 5.4.1 North America 5.4.1.1 United States 5.4.1.2 Canada 5.4.1.3 Mexico 5.4.2 Europe 5.4.2.1 Germany 5.4.2.2 United Kingdom 5.4.2.3 France 5.4.2.4 Italy 5.4.2.5 Spain 5.4.2.6 Rest of Europe 5.4.3 Asia-Pacific 5.4.3.1 China 5.4.3.2 Japan 5.4.3.3 India 5.4.3.4 South Korea 5.4.3.5 Australia 5.4.3.6 Rest of Asia-Pacific 5.4.4 Middle East & Africa 5.4.4.1 GCC 5.4.4.2 South Africa 5.4.4.3 Rest of Middle East & Africa 5.4.5 South America 5.4.5.1 Brazil 5.4.5.2 Argentina 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Amgen Inc. 6.1.2 AstraZeneca PLC 6.1.3 Bayer AG 6.1.4 Johnson and Johnson 6.1.5 Merck & Co. Inc. 6.1.6 F. Hoffmann-La Roche AG 6.1.7 Eli Lilly and Company 6.1.8 Novartis AG 6.1.9 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Organization: Industry Research

Phone: +44 20 3239 8187 / +14242530807

Email: [emailprotected]

Our Other Reports:

Peptone Market, Reduced Iron Powder Market, Poultry Processing Equipment Market

Nonylphenol Ethoxylate Market, Data Center Cooling Market, Polyamide 12 Market

Feed Additives Market, Sputtering Target for Semiconductor Market, Aluminum Plastic Tubes Market

Track-etched Membrane Market, Liquid Chlorine Market, Mooring Light Market

Card Printing Ribbon Market, Intermodal Containers Market, Medium Voltage Ring Main Units Market

, ,

Read the rest here:
Cancer Therapy Market Research by 2020 Top Countries Data, Key Players, Industry Revenue, Demand Status and Investments Plans Forecast to 2024 - The...

Global Thalassemia Market 2020: Potential Growth, Challenges, and Know the Companies Listed-Novartis AG; Teva Pharmaceutical Industries Ltd.;…

Global Thalassemia Marketis expected to rise from its initial estimated value of USD 1.99 billion to a projected value of USD 4.36 billion by 2026, registering a CAGR of 10.29% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing concern and awareness regarding the disease globally.

Get Sample Copy Of This Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-thalassemia-market

Few of the major competitors currently working in the thalassemia market are ApoPharma Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Pfizer Inc.; bluebird bio, Inc.; Acceleron Pharma, Inc.; Incyte Corporation; Kiadis Pharma; Gamida Cell; CELGENE CORPORATION; GlaxoSmithKline plc; Ionis Pharmaceuticals, Inc.; Vifor Pharma; La Jolla Pharmaceutical Company; Lonza and Sangamo Therapeutics.

Major Insights of the Report

Key Developments in the Market:

In April 2019, CELGENE CORPORATION and Acceleron Pharma, Inc. announced that CELGENE had submitted a Biologics License Application (BLA) for luspatercept with the U.S. F.D.A. (United States Food & Drug Administration). This will help in faster commercialization and development of drugs for patients suffering from blood diseases. In January 2019, Vifor Pharma announced positive results from their phase-I trial of VIT-2763 an oral ferroportin inhibitor. The drug being developed for transportation of iron from one cell to another has shown signs in reduction of serum iron in a dose-dependent state. COMPETITIVE ANALYSIS: Global thalassemia market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of thalassemia market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Drivers

Increasing prevalence of the disease globally without any viable treatment options available for curing the disease; this factor is expected to drive the market growth Growth in development of pipeline drugs and development of new therapies because of R&D activities and investments by the various authorities; this factor is expected to drive the market growth

Market Restraint

Lack of viable treatment options commercialized for the treatment of disease/disorder rather than the symptoms associated with the disease; this factor is expected to restrain the market growth High cost of treatment for the disorder is expected to act as a restraint to the market growth

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-thalassemia-market

Segmentation: Global Thalassemia Market

By Thalassemia Type

Alpha Thalassemia Beta Thalassemia

By Therapeutic Class

Iron Chelating Drugs Exjade/Jadenu (deferasirox)

By Pipeline

Gene Therapy LentiGlobin

By End-User

Hospitals Clinics Research Institutes Laboratories

By Geography

North America South America Europe Asia-Pacific Middle East & Africa

Get Full Table Of content @https://www.databridgemarketresearch.com/toc/?dbmr=global-thalassemia-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email:[emailprotected]

More here:
Global Thalassemia Market 2020: Potential Growth, Challenges, and Know the Companies Listed-Novartis AG; Teva Pharmaceutical Industries Ltd.;...

Muscular Dystrophy Association Awards Five Grants Totaling Over $1.6 Million for Amyotrophic Lateral Sclerosis (ALS) Research – BioSpace

NEW YORK, Sept. 30, 2020 /PRNewswire/ --The Muscular Dystrophy Association (MDA) announced today the awarding of five new MDA grants totaling over $1.6 milliontoward research focused on amyotrophic lateral sclerosis (ALS), commonly known as "Lou Gehrig's disease." MDA has devoted over $168 million to ALS research, including $20 million in the last decade.

"We are at a time of unprecedented progress in ALS, thanks in large part to the foundation established by MDA's investments," saysSharon Hesterlee, PhD, chief research officer for MDA. "We now have greater insight into the processes that underlie this disease and the ability to target specific genes where genetic causes are identified."

The newly funded projects will aim to: create a clinical trials platform for testing multiple drugs simultaneously; deploy an ALS Toolkit; continue development of a biobank and database that can be used by ALS researchers .; develop and validate a new gene therapy strategy for ALS and frontotemporal degeneration (FTD), and prepare for a personalized clinical trial of a novel treatment for ALS symptoms, while also researching risk factors and the cause of ALS.

The ALSgrant awards for this grant cycleinclude:

Due to COVID, MDA had to cancel its spring review session. The funding of these projects was reviewed in 2019. For a complete list of individual awards, visit MDA's Grants at a Glance.

Grants being given jointly by MDA and other organizations will be announced separately.

About the Muscular Dystrophy Association

For 70 years, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases throughinnovations in scienceandcare. As the largest source of neuromuscular disease research funding outside of the federal government, MDA has committed more than$1 billion to accelerate the discovery of therapies and cures.Research we have supportedis directly linked to life-changing therapies across multiple neuromuscular diseases.MDA's MOVRis the first and only data hub that aggregates clinical, genetic, and patient-reported data for multiple neuromuscular diseases to improve health outcomes and accelerate drug development. MDA supports thelargest network of multidisciplinary clinics,providing best in class care at more than 150 of the nation's top medical institutions. OurResource Centerprovides one-on-one specialized support, and we offer conferences, events, and materials for families and healthcare providers. During COVID-19, MDA continues to produce virtual events and programming to support our community. For more information, visitmda.org.

View original content to download multimedia:http://www.prnewswire.com/news-releases/muscular-dystrophy-association-awards-five-grants-totaling-over-1-6-million-for-amyotrophic-lateral-sclerosis-als-research-301141830.html

SOURCE Muscular Dystrophy Association

Link:
Muscular Dystrophy Association Awards Five Grants Totaling Over $1.6 Million for Amyotrophic Lateral Sclerosis (ALS) Research - BioSpace

Precision Cancer Therapies Market Outlook 2020: Global Topmost Companies, Size, Trends And Upcoming Forecasts 2026 – The Market Records

A new research study has been presented by Dataintelo.com offering a comprehensive analysis on the Global Precision Cancer Therapies Market where user can benefit from the complete market research report with all the required useful information about this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments.

The Precision Cancer Therapies Market report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunity analysis, strategic market growth analysis, product launches, and technological innovations.

Get a Free Sample Copy of the Precision Cancer Therapies Market Report with Latest Industry Trends @ https://dataintelo.com/request-sample/?reportId=90959

Major Players Covered in this Report are: Abbott Laboratories Bayer HealthCare GlaxoSmithKline OncoGenex Pharmaceuticals Hospira Boehringer Ingelheim AstraZeneca Aveo Pharmaceuticals

Global Precision Cancer Therapies Market Segmentation This market has been divided into Types, Applications, and Regions. The growth of each segment provides an accurate calculation and forecast of sales by Types and Applications, in terms of volume and value for the period between 2020 and 2026. This analysis can help you expand your business by targeting qualified niche markets. Market share data is available on the global and regional level. Regions covered in the report are North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Research analysts understand the competitive strengths and provide competitive analysis for each competitor separately.

By Types: Hormone Therapy Immunotherapies Targeted Therapy Monoclonal Antibody Therapy Gene Therapy

By Applications: Hospitals Diagnostic Centers Oncology Clinics Research Institutes

To get Incredible Discounts on this Premium Report, Click Here @ https://dataintelo.com/ask-for-discount/?reportId=90959

Global Precision Cancer Therapies Market Regions and Countries Level Analysis Regional analysis is a highly comprehensive part of this report. This segmentation sheds light on the sales of the Precision Cancer Therapies on regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

The report offers an in-depth assessment of the growth and other aspects of the market in key countries including the US, Canada, Mexico, Germany, France, the UK, Russia, Italy, China, Japan, South Korea, India, Australia, Brazil, and Saudi Arabia. The competitive landscape chapter of the global market report provides key information about market players such as company overview, total revenue (financials), market potential, global presence, Precision Cancer Therapies sales and revenue generated, market share, prices, production sites and facilities, products offered, and strategies adopted. This study provides Precision Cancer Therapies sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Make an Inquiry of this Report @ https://dataintelo.com/enquiry-before-buying/?reportId=90959

Why Choose Us:

Table of Contents1. Executive Summary 2. Assumptions and Acronyms Used 3. Research Methodology 4. Market Overview 5. Global Market Analysis and Forecast, by Types 6. Global Market Analysis and Forecast, by Applications 7. Global Market Analysis and Forecast, by Regions 8. North America Market Analysis and Forecast 9. Latin America Market Analysis and Forecast 10. Europe Market Analysis and Forecast 11. Asia Pacific Market Analysis and Forecast 12. Middle East & Africa Market Analysis and Forecast 13. Competition Landscape

About DataIntelo: DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex Mathews Address: 500 East E Street, Ontario, CA 91764, US. Phone No: US: +1 909 545 6473 | IND: +91-7000061386 Email: [emailprotected] Website: https://dataintelo.com

Read more from the original source:
Precision Cancer Therapies Market Outlook 2020: Global Topmost Companies, Size, Trends And Upcoming Forecasts 2026 - The Market Records

Muscular Dystrophy Association Awards 15 Grants Totaling More Than $4 Million for Neuromuscular Disease Research – Stockhouse

NEW YORK , Sept. 23, 2020 /PRNewswire/ -- The Muscular Dystrophy Association (MDA) announced today the awarding of 15 new MDA grants totaling more than $4 million toward research focused on a variety of neuromuscular diseases (NMDs), including Duchenne muscular dystrophy (DMD), Charcot-Marie-Tooth disease (CMT), Becker's muscular dystrophy (BMD), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD). This round of grant funding reinforces MDA's unwavering commitmentin the face of declining income due to the COVID-19 pandemicto the progress of neuromuscular disease research and builds on the more than $1 billion MDA has already invested in research to uncover new treatments and cures for NMDs since its inception. Some grants will go into effect this year, while others will be awarded in 2021.

"We continue to fund the most innovative research that will lead us to cures for a range of neuromuscular diseases," says Sharon Hesterlee, PhD, executive vice president and chief research officer for Muscular Dystrophy Association. "We have already seen our investment pay off with the first effective neuromuscular disease therapies, and these grantees are pushing the envelope even further in diseases once thought incurable."

Dr. Hesterlee added, "Although COVID led the cancellation of MDA's spring review session, we are pleased to announce the funding of these projects, which were reviewed in 2019."

The newly funded projects will aim to advance research discoveries and new therapy development in multiple areas. The awarded grants will fund studies to further advance our understanding of genetic causes of and risk factors for NMDs, investigate new approaches to developing gene therapies and other innovative potential treatments, including stopping disease progression and improving genetic testing technologies.

For a complete list of individual awards for this grant cycle, visit MDA's website and explore the Grants at a Glance section. Highlights from the grant awards for this grant cycle include:

ALS grants will be announced separately later this month, as will grants being given jointly by MDA and other organizations.

About the Muscular Dystrophy Association For 70 years, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases. We do this through innovations in science and innovations in care . As the largest source of funding for neuromuscular disease research outside of the federal government, MDA has committed more than $1 billion since our inception to accelerate the discovery of therapies and cures. Research we have supported is directly linked to life-changing therapies across multiple neuromuscular diseases. MDA's MOVR is the first and only data hub that aggregates clinical, genetic, and patient-reported data for multiple neuromuscular diseases to improve health outcomes and accelerate drug development. MDA supports the largest network of multidisciplinary clinics providing best in class care at more than 150 of the nation's top medical institutions. Our Resource Center serves the community with one-on-one specialized support, and we offer educational conferences, events, and materials for families and healthcare providers. Each year thousands of children and young adults learn vital life skills and gain independence at summer camp and through recreational programs, at no cost to families. During the COVID-19 pandemic, MDA continues to produce virtual events and programming to support our community when in-person events and activities are not possible. MDA's COVID-19 guidelines and virtual events are posted at mda.org/COVID19 . For more information, visit mda.org .

View original content to download multimedia: http://www.prnewswire.com/news-releases/muscular-dystrophy-association-awards-15-grants-totaling-more-than-4-million-for-neuromuscular-disease-research-301136519.html

SOURCE Muscular Dystrophy Association

Read the original post:
Muscular Dystrophy Association Awards 15 Grants Totaling More Than $4 Million for Neuromuscular Disease Research - Stockhouse

Thalassemia Treatment Market projected to expand at a CAGR of 7.9% from 2018 to 2026 – The Daily Chronicle

Transparency Market Research (TMR)has published a new report titled, Thalassemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026.According to the report, theglobal thalassemia treatment marketwas valued at US$ 842.0 Mn in 2017 and is projected to expand at a CAGR of 7.9% from 2018 to 2026. Increase in R&D investment by key players for developing new drugs for treating thalassemia and rise in demand for chelating therapy are anticipated to fuel the growth of the global market from 2018 to 2026. Asia Pacific and Middle East & Africa are expected to dominate the global market owing to increase in prevalence of thalassemia disorder and high adoption of chelation therapy & blood transfusion for treatment by doctors as well as patients. The market in Asia Pacific is projected to expand at the fastest CAGR during the forecast period. Growth of the market in the region is attributed to large base of private clinics and hospitals, rise in number of thalassemia population requiring chelation therapy services after spleen surgery, and surge in adoption of blood transfusion among patients. The thalassemia treatment market in Latin America is likely to expand at a moderate growth rate during the forecast period.

Request Brochure for Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=44462

Value Added Features in Thalassemia Treatments to Propel Global Market

The global thalassemia treatment market is projected to be driven by value added features offered by various thalassemia drug manufacturing companies in order to streamline the day to day work flow and increase revenue. The thalassemia treatment provides limited range of features and benefits ranging from patient pain heeling remedies to treatment procedures. For instance, very less number of people go for the much beneficial chelation therapy. These features help physicians and nurses to streamline the chelation therapy required for patients to maintain their daily workflow efficiently and effectively. Key players offering thalassemia treatment are coming up with value added features such as bone marrow transplantation, stem cell regeneration, gene editing methodologies, and effective modality features used for drug manufacturing along with creating a prominent candidate molecule for drugs. These features can reduce the overall operating cost and improve the overall effectiveness and efficiency of treatment practices. Companies are focusing on the development of combined drug therapy in their system to effectively integrate chelating therapy or other treatment procedure at an affordable cost. These value added features save time for physicians and help improve thalassemia patient survival performance.

Request for Analysis of COVID19 Impact on Thalassemia Treatment Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=44462

Chelation Therapy to be Highly Lucrative Segment

Traditionally, blood transfusion based on type of thalassemia treatment was the most commonly used procedure among thalassemia patients. This treatment type was associated with availability of donor and cost of treatment procedure. Moreover, chelation therapy based on thalassemia treatment are priced on perpetual license model and are expensive. Chelation therapy treatment enables patients to practice intensive therapy to treat acute iron overload leading to 90% recovery among thalassemia patients. These chelation therapy based treatments address specific challenges faced during the treatment procedure. The chelation therapy treatment facilitates benefits such as pain relief, and increase in motion of blood flow among patients.

Asia Pacific Presents Significant Opportunities

North America and Europe accounted for major share of the global thalassemia treatment market in 2017 and are likely to gain market shares by 2026. High rate of immigration from tropical regions, increasing health care budgets by governments, and government initiatives to promote thalassemia treatment technique contributed to the leading share of these regions. Asia Pacific is projected to be the most attractive market for thalassemia treatment, with highest attractiveness index. The market in Asia Pacific is expected to expand at a high CAGR of 9% during the forecast period due to large number of thalassemia patients opting for chelation therapy in developing countries such as India and China. Well-established health care facilities, medical tourism for treatment of thalassemia, and high adoption of blood transfusion safety technique in countries such as Turkey and GCC Countries are likely to drive the market in Middle East & Africa. The market in Latin America is poised to expand at a moderate growth rate during the forecast period.

Buy Thalassemia Treatment Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=44462&ltype=S

Trend of R&D among Leading Players to Increase Geographic Presence

The report also provides profiles of leading players operating in the global thalassemia treatment market. bluebird bio, Inc., Acceleron Pharma, Inc., Novartis AG, Celgene Corporation, and Shire plc (Takeda Pharmaceuticals) are the leading players operating in the global market. Companies operating in the thalassemia treatment market aim to increase geographic presence and research & development through strategic acquisitions and collaborations with leading players in respective domains and region. In December 2017, Shire plc committed to pay approximately US$ 1,409.9 Mn to contract vendors for administering and executing clinical trials. Other prominent players operating in the global thalassemia treatment include Incyte Corporation, Kiadis Pharma, Gamida Cell, Celgene Corporation, and Bellicum Pharmaceuticals.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Link:
Thalassemia Treatment Market projected to expand at a CAGR of 7.9% from 2018 to 2026 - The Daily Chronicle

Genomics Market to Rise at 19.5% CAGR and Reach USD 82.60 Billion by 2027; Advances in Diagnostic Applications will Lead to a Wider Product Adoption,…

September 29, 2020 08:39 ET | Source: Fortune Business Insights

Pune, Sept. 29, 2020 (GLOBE NEWSWIRE) -- The global genomics market size is projected to reach USD 82.60 billion by the end of 2027. The massive investments in the research and development of efficient products will have a massive impact on the growth of the market in the coming years.

According to a report published by Fortune Business Insights, titled Genomics Market Size, Share & COVID-19 Impact Analysis, By Type (Products (Instruments & Software and Consumables) and Services), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Microarray, Sanger Sequencing, and Others), By Application (Diagnostics, Research, and Others), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centers, Pharmaceutical & Biotechnological Companies, Contract Research Organization (CROs)), and Regional Forecast, 2020-2027, the market was worth USD 18.85 billion in 2019 and will exhibit a CAGR of 19.5% during the forecast period 2020-2027.

Genomics is a concept that involves the human gene and sequencing for treatment and study of several diseases or potential diseases. The study of human genetics helps identify and track critical diseases, with equal focus on the qualities and behaviour of a specific individual. In the past few years, genomics has contributed to the growth of numerous similar branches including the popular precision medicine.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/genomics-market-100941

The massive investments in the research and development of genomics and genomic sequencing will have a positive impact on the growth of the overall market in the coming years. The presence of several large scale companies has had a massive impact on the growth of the market in recent years and the influx of start-ups will create opportunities for growth in the foreseeable future.

Recent Clinical Studies have Indicated the Potential of Genomics to Tracking Patterns of Covid-19 Spread

The recent coronavirus outbreak has created a sense of panic among businesses across the world. Although healthcare industry has witnessed a contrasting impact, as compared to a few other sectors, there has been a recent surge in the need for healthcare professionals. The lack of skilled labour is consequential to the hesitancy among workers due to the severity of the disease. Although there are several ongoing research activities associated with the treatment of the coronavirus, there has been little success in this field.

Accounting to increasing cases of Covid-19 across the world, researchers are focusing on implementing preventive and precautionary measures through newer concepts. The excessive research associated with the use of genomics in Covid-19 pandemic has yielded a few successful measures. As a result, genomics has recently attracted attention from across the world.

The whole world is fighting the novel coronavirus. Sectors and industries are devasted due to the major loss caused by COVID-19 in business. The authorities of several countries have initiated lockdown to prevent the spread of this deadly virus. Such plans have caused disturbances in the production and supply chain. But, with time and resolution, we will be able to combat this stern time and get back to normality. Our well-revised reports will help companies to receive in-depth information about the present scenario of every market so that you can adopt the necessary strategies accordingly.

To get to know more about the short-term and long-term impacts of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/industry-reports/genomics-market-100941

Constant Product Innovations are Consequential to Increasing R&D Efforts

The report encompasses several factors that have contributed to the growth of the overall market in recent years. Among all factors, the increasing number of product innovations, driven by rising investments in the research and development of the product, has made the highest impact on the growth of the market. In April 2020, Eurofins announced the launch of a new product in the genome sequencing space.

The company introduced SARS-CoV 2 full length genome sequencing, a product that is categorized under the next-generation (NGS) sequencing category. Increasing number of such product innovations will have a positive impact on the growth of the overall market in the coming years.

North America to Emerge Dominant; Increasing Activities associated with Whole-genome Sequencing will Emerge in Favor of Market Growth

The report analyses the ongoing market trends across five major regions, including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among all regions, the market in North America is projected to emerge dominant in the coming years. The increasing research activities associated with whole-genome sequencing by private companies as well as government organizations will contribute to the growth of the regional market.

As of 2019, the market in North America was worth USD 8.27 billion and this value is projected to rise at a considerable pace in the coming years. The market in Asia Pacific will derive growth form the efforts put in towards genetic sequencing by countries such as China.

Quick Buy - Genomics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100941

List of companies profiled in the Genomics Market report:

Industry Developments:

February 2020: Nebula Genomic announced the launch of a new product that will offer whole genome sequencing at US$ 299 to its customers.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/genomics-market-100941

Table of Contents:

TOC Continued.!

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/genomics-market-100941

Have a Look at Related Reports:

Next-Generation Sequencing (NGS) Market Share and Global Trend By Type (Products, Instruments & Software, Consumables, Services), By Application (Diagnostics, Research), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centres, Pharmaceutical & Biotechnological Companies, Contract Research Organization) & Geography Forecast till 2026

Molecular Diagnostics Market Share and Global Trend By Product Type (Instruments Reagents & Consumables), Application (Infectious Disease, Blood Screening, Histology & Oncology), Technique (Hospitals Amplification, Hybridization & Sequencing Techniques), End User (Hospitals, Clinical & Pathology Labs) and Geography Forecast till 2025

Polymerase Chain Reaction (PCR) Market Share & Industry Analysis, By Type (Standard PCR, Real-time PCR, and Digital PCR), By Product (Instruments and Reagents & Consumables), By Indication (Infectious Diseases, Oncology, Genetic Disorders, and Others), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Industries, Diagnostic Centers, and Academic & Research Organizations), and Regional Forecast, 2019-2026

Hormone Replacement Therapy (HRT) Market Share & Industry Analysis, By Therapy Type (Estrogen and Combinations Replacement Therapy, Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy), By Indication (Menopause, Hypothyroidism, Male Hypogonadism, and Growth Hormone Deficiency), By Route of Administration (Oral, Transdermal, and Parenteral), By Distribution Channel (Hospital Pharmacies), and Regional Forecast, 2019-2026

Heart Valves Market Share & Industry Analysis, By Product Type (Replacement (Aortic, Mitral, and Others), and Repair), By Valve Type (Tissue Valve and Mechanical Valve), By Procedure (Surgical and Transcatheter), By End User (Hospitals, and Specialty Clinics & Others), and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: sales@fortunebusinessinsights.com Fortune Business Insights LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/genomics-market-9172

See the original post:
Genomics Market to Rise at 19.5% CAGR and Reach USD 82.60 Billion by 2027; Advances in Diagnostic Applications will Lead to a Wider Product Adoption,...

Meet the 2020 finalists for the $1 million Sanford Lorraine Cross Award honoring innovation in medical science – PRNewswire

SIOUX FALLS, S.D., Sept. 29, 2020 /PRNewswire/ -- Sanford Health, the largest provider of rural healthcare in the country, today announced the finalists for the biennial Sanford Lorraine Cross Award which honors life-changing breakthroughs and innovations in medical science.

The 2020 finalists are:

Mark Denison, MD Director of Pediatric Infectious Diseases Principle Investigator (Denison Lab) Departments of Pediatrics and Pathology, Vanderbilt University

Carl June, MD Director of the Center for Cellular Immunotherapies Perelman School of Medicine, University of Pennsylvania

Michael Welsh, MD Investigator (Howard Hughes Medical Institute) Director (Pappajohn Biomedical Institute) Carver College of Medicine, University of Iowa

Sanford Health is the only health system in the country to award a $1 million prize for achievements in the medical sciences. A winner will be selected at a special ceremony in Sioux Falls, South Dakota on Tuesday, December 8, 2020.

While traditional awards in the medical sciences focus on the significance of the contribution of a researcher or clinician, the Sanford Lorraine Cross Award celebrates the role that the award candidate has played in bringing a new emerging transformative medical innovation across the finish line to patients, and their efforts in overcoming challenges, forging collaborations, and ensuring a successful outcome.

Finalists for the Sanford Lorraine Cross Award are determined through a rigorous selection process that uses machine learning to identify innovative areas of discovery and breakthrough science. The candidate selection is then focused on the areas with the most promising transformative potential for patients. An interdisciplinary scientific advisory board narrowed down the top areas of innovation. The individuals who have made the greatest contribution in these three areas are then identified as the finalists.

"Sanford Health has a long history of relentlessly challenging the status quo to improve health care," said Kelby Krabbenhoft, CEO, Sanford Health. "The Sanford Lorraine Cross Award honors someone pioneering that change with a medical breakthrough, innovation or treatment to transform global health. It starts with a $1 million prize, and it continues with a life-changing impact for us all."

The award is named after the Cross of Lorraine, a global symbol first chosen as emblematic for those who took action against disease in 1902 at the International Tuberculosis Congress in Berlin. In recent history, Sanford Health has used it to symbolize profound innovation and progress in the medical sciences and also includes the image in its own institutional logo.

The Sanford Lorraine Cross Award is supported in perpetuity through an endowment established by donors to the Sanford Health Foundation. Donors who invest $1 million or more are honored as members of the Founders Circle, a distinguished group celebrated for its visionary generosity. These individuals are united by their passion for creating a better tomorrow, inspiring future generations of courageous innovators, and leaving a legacy of health and healing.

The December awards event will be livestreamed on Sanford Health's social media channels on Twitter, Facebook and YouTube, and regularly covered on Sanford Health News.

Here's a closer look at the 2020 Lorraine Cross finalists:

Mark Denison, MD

Dr. Mark Denison of Vanderbilt University has studied coronaviruses since the 1980s. In 2007, his lab discovered that coronaviruses have a protein that acts as a powerful proofreader during replication, meaning that the virus can self-correct errors in its RNA sequence.

This makes coronaviruses difficult to treat, but Dr. Denison and his team theorized that if they could slip past the proofreaders, they could prevent the virus from growing. Through a partnership with Gilead Sciences, they discovered Remdesivir, a drug that can evade the proofreading system and terminate the growth, thus killing the virus.

Though Remdesivir was shelved after failed attempts to treat hepatitis and Ebola, it has experienced a rebirth during today's COVID-19 pandemic and is undergoing clinical trials for treatment.

Since the spark of COVID-19, Dr. Denison's story is the world's story. His work on Remdesivir has received coverage from The New Yorker, CNN, The New York Timesand others.

Without his early discovery of this proofreading mechanism, it is unlikely scientists would have been able to jump start therapeutic solutions for the current COVID-19 pandemic.

Carl June, MD

T cells are like the body's security guards, recognizing harmful intruders and triggering an immune response. Dr. Carl June of the University of Pennsylvania, working with colleague Dr. Bruce Levine, was able to reprogram selected T cells to recognize and destroy leukemia cancer cells.

This therapy is now named KYMRIAH by Novartis and is FDA-approved to treat acute lymphoblastic leukemia (ALL).

In 2010, June and Levine treated their first patient a retired 65-year-old corrections officer named Bill Ludwig. After just a few infusions, Ludwig fell severely ill and spent a week in the ICU. Then, all of the sudden, he woke up and found the masses had disappeared.

A second patient, Emily Whitehead, had relapsed twice at the age of seven with an extremely aggressive form of leukemia. Like Ludwig, Whitehead got severely ill as the therapy tried to rid her of her cancer. However, this time Dr. June recalled an arthritis drug (from his daughter's struggle with juvenile arthritis) that could manage her side effects.

The story of Emma Whitehead was featured in a 2012 article in the New York Timesand covered in Forbes, PARENTSMagazine and the PBS documentary "Cancer: The Emperor of All Maladies."

Michael Welsh, MD

Dr. Michael Welsh isa pulmonary physician who wanted to know how human airways work, particularly howsalt ions moveacross the airway wall. This led him to study cystic fibrosis (CF),an inherited disease that causes lifelong vulnerability todestructive lunginfections and an early death.

He discovered that the CFTR gene instructs the cell to make a channelfor chloride.This was a monumentalbreakthroughbecause it linked the genetics and the lung infections.Importantly, it also clearly identified thetarget that needed repair.

He then discovered ways that different inherited mutations in the CFTRgene disrupt the chloride channel.Thatwork providedthe blueprint that has continued to guide therapeuticdevelopment.He demonstrated that thecommon CF mutation could becorrected in the lab, a discovery that ignited CF drugdevelopment and provided the confidence, knowledge and tools thatensured success.His workhas been widely covered, including in theThe New York Times.

The excitingadvances arising from Dr. Welsh's research have dramatically changed the livesof people withCF.Today, 90%of CF patients have ahighly effective therapy.His discoverieswere instrumental in arecent finding, published with colleaguesin the March 2019 journalNature, that an approved drug normally used totreat fungal infections could also do the job of theCFTR channel.While additional treatmentswill also be developed, the fundamental properties required to treat the defectremain those defined by the pioneering work of Welsh.

About Sanford Health Sanford Health, one of the largest health systems inthe United States, is dedicated to the integrated delivery of health care, genomic medicine, senior care and services, global clinics, research and affordable insurance. Headquartered inSioux Falls, South Dakota, the organization includes 46 hospitals, 1,400 physicians and more than 200 Good Samaritan Society senior care locations in 26 states and 10 countries. Learn more about Sanford Health's transformative work to improve the human condition atsanfordhealth.orgorSanford Health News.

Media Contact: Angela Dejene [emailprotected] 218-280-0148

SOURCE Sanford Health

Follow this link:
Meet the 2020 finalists for the $1 million Sanford Lorraine Cross Award honoring innovation in medical science - PRNewswire

Endothelial Dysfunction Industry 2020-2025 Market Analysis by Size, Share, Growth, Regional, Manufactures, Application and Forecast Research Report -…

The Asia-Pacific Endothelial Dysfunction market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2025. Endothelium dysfunction can be defined as partial or complete loss of balance between vasodilating and vasoconstricting substances produced by the endothelium.

Ask for Sample Copy of This Report @https://www.orianresearch.com/request-sample/875202.

The Global Endothelial Dysfunction Industry based on geographic classification is studied for industry analysis, size, share, growth, trends, segment, top company analysis, outlook, manufacturing cost structure, capacity, supplier and forecast to 2025. Along with the reports on the global aspect, these reports cater regional aspects as well as global for the organizations

Top Key Vendors:

Abbott Laboratories Chugai Pharmaceutical Co. Ltd. Johnson & Johnson Glucox Biotech AB Stealth Peptides Inc

Rise in number of obese populations, reduced physical activities and diabetes leading to increase in chances of acquiring cardiovascular diseases will propel the market growth in the forecast period. Stringent regulation regarding the drug will hamper the market growth in the forecast period. Advances in recombinant and gene therapy are also favoring the growth of endothelial dysfunction drugs uptake and can be an opportunity area for new entrants in the market.

Based on application, the market is segmented into, hospital, clinics among others.

Based on diagnosis, the market is segmented into, coronary circulation, angiography of coronary artery.

Based on region the market is segmented into China, India, Japan, South Korea, Taiwan, Southeast Asia, and Australia.

Global Endothelial Dysfunction Industry is spread across 121 pages, profiling 05 companies and supported with tables and figures.

Inquire more or share a question if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/875202.

Key Benefits of the Report: * Global, Regional, Country, Learning Module, and Type Market Size and Forecast from 2014-2025-Provide attractive market segments and associated growth opportunities * Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies * Identification of key companies that can influence this market on a global and regional scale * Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies * Detailed insights on emerging regions, product & Learning Module, and competitive landscape with qualitative and quantitative information and facts

Target Audience: * Endothelial Dysfunction providers * Traders, Importer and Exporter * Raw material suppliers and distributors * Research and consulting firms * Government and research organizations * Associations and industry bodies.

Order a copy of Global Endothelial DysfunctionMarket Report 2020 @https://www.orianresearch.com/checkout/875202

TABLE OF CONTENT

Introduction

Methodology & Scope

Global Endothelial Dysfunction Market Overview

Asia-Pacific Endothelial Dysfunction Market by Diagnosis type

Asia-Pacific Endothelial Dysfunction Market by Application

Asia-Pacific Endothelial Dysfunction Market by Region

Competitive Landscape

Company Profiles

End of TOC

About Us Orian Researchis one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Our Other Reports:

https://www.openpr.com/news/2115906/covid-19-impact-analysis-on-optogenetics-industry-2020-2026

See the original post here:
Endothelial Dysfunction Industry 2020-2025 Market Analysis by Size, Share, Growth, Regional, Manufactures, Application and Forecast Research Report -...

The Global CRISPR Technology Market Size Is Seeing Exponential Growth Due To The Application Of CRISPR Technology In Treating COVID-19 – GlobeNewswire

September 24, 2020 09:00 ET | Source: The Business Research Company

LONDON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- (Companies Included: Crispr Therapeutics, Thermo Fisher Scientific, Intellia Therapeutics, Horizon Discovery, and Synthego Corporation)

In another instance, in early May, the US Food and Drug Administration (FDA) granted Sherlock Biosciences an emergency use authorization (EUA) for its COVID-19 diagnostic assay, beating out other companies and academic groups trying to use the powerful gene-editing technology to figure out who is infected with the novel coronavirus. Sherlocks test is the first FDA-authorized use of CRISPR technology for anything. Sherlocks test is a molecular diagnostic, intended to identify people who have acute SARS-CoV-2 infection. It capitalizes on a CRISPR-based technology developed in the lab of Feng Zhang, a scientist at Broad Institute of MIT and Harvard and a cofounder of Sherlock.

The Business Research Companys report titled CRISPR Technology Global Market Report 2020-30: Covid 19 Growth And Change covers the CRISPR market 2020, CRISPR technology market share by company, global CRISPR technology market analysis, global CRISPR technology market size, and CRISPR technology market forecasts. The report also covers the global CRISPR technology market and its segments. The CRISPR technology market share is segmented by product type into Cas9 and gRNA, design tool, plasmid and vector, and other delivery system products. The CRISPR technology market share is segmented by end-user into biopharmaceutical companies, agricultural biotechnology companies, academic research organizations, and contract research organizations (CROs). By application, it is segmented into biomedical, agriculture, diagnostics, and others.

Request A Sample Of The Global CRISPR Technology Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3272&type=smp

The global CRISPR technology market value is expected to grow from $685.5 million in 2019 to $1,654.2 million in 2023 at a compound annual growth rate (CAGR) of 24.6%. The application of CRISPR technology as a diagnostic tool is expected to boost CRISPR technology market growth during the period. The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19. In May 2020, the US FDA (Food and Drug Administration) announced emergency use authorization of Sherlock BioSciences Inc.s Sherlock CRISPR SARS-CoV-2 kit, which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test.

This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract, and fluid in the lungs from bronchoalveolar lavage specimens. This diagnostic kit has high specificity and sensitivity, and does not provide false negative or positive results. Widening the application of CRISPR technology for the diagnosis of infectious diseases will further increase the demand for CRISPR technology products and services and drive the CRISPR market 2020.

Several advancements in CRISPR technology are trending in the market. Advancements in technology will help in reducing errors, limiting unintended effects, improving the accuracy of the tool, widening its applications, developing gene therapies, and more. Scientists, researchers and companies are increasingly developing advanced CRISPR technologies for more precise editing and to get access to difficult to reach areas of human genome. For instance, in March 2020, scientists at University of Toronto developed CHyMErA, a CRISPR-based tool for more versatile genome editing. Similarly, in March 2020, researchers at New York genome center developed a new CRISPR screening technology to target RNA, including RNA of novel viruses like COVID.

In November 2019, researchers at ETH Zurich, Switzerland, swapped CAS9 enzyme for Cas 12a, that allowed the researchers to edit genes in 25 target sites. It is also estimated that hundreds of target sites can be modified using the above method. In October 2019, a team from MIT and Harvard developed new CRISPR genome editing approach called prime editing by combining CRISPR-Cas9 and reverse transcriptase into a single protein. The prime editing has the potential to directly edit human cells with high precision and efficiency.

The CRISPR technology market share consists of sales of CRISPR technology products and services, which is a gene-editing technology that allows researchers to alter DNA sequences and modify gene function. The revenue generated by the market includes the sales of products such as design tools, plasmid & vector, Cas9 & gRNA, and libraries & delivery system products and services that include design & vector construction, screening and cell line engineering. These products and services are used in genome editing/genetic engineering, genetically modifying organisms, agricultural biotechnology and others, which include gRNA database/gene library, CRISPR plasmid, and human stem cell & cell line engineering.

CRISPR Technology Global Market Report 2020-30: Covid 19 Growth And Change is one of a series of new reports from The Business Research Company that provide market overviews, analyze and forecast market size and growth for the whole market, CRISPR technology market segments and geographies, CRISPR technology market trends, CRISPR technology market drivers, CRISPR technology marketrestraints, CRISPR technology market leading competitors revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies. The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modellers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitors approaches.

Here Is A List Of Similar Reports From The Business Research Company

Organ-On-Chips Market - By Models (Lung-On-Chip, Heart-On-Chip, Liver-On-Chip, Intestine-On-Chip, Kidney-On-Chip And More), By Applications, And By Region, Opportunities And Strategies Global Forecast To 2023

Healthcare Services Market -By Type (Hospitals And Clinics, Physicians, Nursing Care, Dental Services, Laboratory Services, Ambulance Services And Others), By End User Gender, And By Region, Opportunities And Strategies Global Forecast To 2022

Biobank Market - By Specimens Type (Blood Products, Cell Lines, Nucleic Acids And Human Tissues), And By Region, Opportunities And Strategies Global Forecast To 2023

Gene Editing Global Market Report 2020

Sequencing Market By Type (Next Generation Sequencing, Third Generation Sequencing And Sanger Sequencing), By Products (Consumables, Software, Sequencing Services And Instruments), By Regions And By Trends Global Forecast To 2023

Nucleic Acid Based Gene Therapy Market Global Report 2020

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

The Worlds Most Comprehensive Database

The Business Research Companys flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

View original post here:
The Global CRISPR Technology Market Size Is Seeing Exponential Growth Due To The Application Of CRISPR Technology In Treating COVID-19 - GlobeNewswire